Grufity logoGrufity logo

VERV

21.84USD-0.46(-2.06%)Market Closed

Verve Therapeutics Inc

Market Summary

USD21.84-0.46Market Closed
-2.06%

VERV Alerts

VERV Stock Price

RSI Chart

Valuation

Market Cap

2.4B

Price/Earnings

-19.49

Price/Cashflow

-22.25

Price/Earnings

Profitability

Return on Equity

-42.25%

Return on Assets

-38.61%

Fundamentals

Earnings

Earnings (TTM)

-147.6M

Earnings Y/Y

-98.65%

Earnings Q/Q

-10.36%

Price Action

52 Week Range

43.00
(Low)(High)

Last 7 days

-2.5%

Last 30 days

-46.3%

Last 90 days

-42.5%

Trailing 12 Months

-34.1%

Financial Health

Current Ratio

11.55

Investor Care

Shares Dilution (1Y)

27.89%

Diluted EPS (TTM)

-1.89

Financials for Verve Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets107.7%673324349384411
  Current Assets88.1%562299329367394
    Cash Equivalents280.1%277739164148
  Net PPE22.7%15121177
Liabilities349.0%12528182726
  Current Liabilities12.3%2926152220
Shareholder's Equity84.9%548296331357385
  Retained Earnings-17.5%-303.15-257.96-217.02-186.85-155.51
  Additional Paid-In Capital53.5%852555549544540
Accumulated Depreciation20.5%43322
Shares Outstanding24.1%6049494948
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-7.1%-117.48-109.66-96.25-77.88-64.81
  Share Based Compensation24.3%19151175
Cashflow From Investing77.8%-44.63-201.43-190.72-239.10-170.23
Cashflow From Financing22132.7%2911284377376

Risks

What is the probability of a big loss on VERV?

81.6%


Probability that Verve Therapeutics stock will be more than 20% underwater in next one year

81.6%


Probability that Verve Therapeutics stock will be more than 30% underwater in next one year.

79.0%


Probability that Verve Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VERV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on VERV

Which funds bought or sold VERV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
1,077,000
1,568,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-
-
-%
2022-11-15
Pinz Capital Management, LP
SOLD OFF
-100
-792,000
-
-%
2022-11-15
Alphabet Inc.
UNCHANGED
-
209,275,000
376,958,000
19.25%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
STATE STREET CORP
ADDED
362.57
86,925,000
96,174,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
83.51
1,920,000
2,534,000
-%
2022-11-14
Covestor Ltd
REDUCED
-54.55
-
-
-%
2022-11-14
JPMORGAN CHASE & CO
ADDED
41.62
45,202,000
65,901,000
0.01%
2022-11-14
AMERICAN INTERNATIONAL GROUP, INC.
ADDED
24.95
478,000
742,000
-%

1–10 of 41

Latest Funds Activity

Are funds buying VERV calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own VERV

Verve Therapeutics News

GuruFocus.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verve Therapeutics, Inc..10 hours ago

VERV Fair Value

Recent SEC filings of Verve Therapeutics

View All Filings
Date Filed Form Type Document
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 07, 2022
8-K
Current Report
Nov 07, 2022
10-Q
Quarterly Report
Nov 04, 2022
4
Insider Trading
Nov 04, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Oct 05, 2022
4
Insider Trading

Latest Insider Trading transactions for VERV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-04
GV 2017 GP, L.L.C.
SOLD
-
-
-48,583
-
2022-11-04
GV 2017 GP, L.L.C.
SOLD
-1,512,800
31.1386
-48,583
-
2022-11-04
GV 2017 GP, L.L.C.
SOLD
-1,512,810
31.1386
-48,583
-
2022-11-04
Yeshwant Krishna
SOLD
-1,512,810
31.1386
-48,583
-
2022-11-04
Yeshwant Krishna
SOLD
-
-
-48,583
-
2022-11-03
Yeshwant Krishna
SOLD
-1,625,500
32.7933
-49,568
-
2022-11-03
Yeshwant Krishna
SOLD
-
-
-49,569
-
2022-11-03
GV 2017 GP, L.L.C.
SOLD
-1,625,500
32.7933
-49,568
-
2022-11-03
GV 2017 GP, L.L.C.
SOLD
-1,625,530
32.7933
-49,569
-
2022-11-03
GV 2017 GP, L.L.C.
SOLD
-
-
-49,569
-

1–10 of 50

Sekar Kathiresan
110
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Collaboration Revenue$ 929$ 0$ 929$ 0
Operating expenses:    
Research and development35,19717,49592,81142,263
General and administrative9,5926,00726,09512,264
Total operating expenses44,78923,502118,90654,527
Loss from operations(43,860)(23,502)(117,977)(54,527)
Other (expense) income:    
Change in fair value of antidilution rights liability000(25,574)
Change in fair value of success payment liability(3,306)700(691)(8,954)
Interest and other income, net1,976532,36678
Total other (expense) income, net(1,330)7531,675(34,450)
Net loss$ (45,190)$ (22,749)$ (116,302)$ (88,977)
Net loss per common share attributable to common stockholders, basic$ (0.79)$ (0.47)$ (2.26)$ (4.52)
Net loss per common share attributable to common stockholders, diluted$ (0.79)$ (0.47)$ (2.26)$ (4.52)
Weighted-average common shares used in net loss per share attributable to common stockholders, basic57,207,12547,992,77351,516,03719,698,450
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted57,207,12547,992,77351,516,03719,698,450
Comprehensive Loss:    
Net loss$ (45,190)$ (22,749)$ (116,302)$ (88,977)
Other comprehensive income (loss):    
Unrealized income (loss) on marketable securities18(5)(692)(10)
Comprehensive loss$ (45,172)$ (22,754)$ (116,994)$ (88,987)

VERV Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 277,019$ 64,330
Marketable securities273,691296,112
Collaboration receivable9290
Prepaid expenses and other current assets9,9916,686
Total current assets561,630367,128
Property and equipment, net15,1597,224
Restricted cash4,8245,237
Operating lease right-of-use assets91,3321,839
Other long term assets4102,696
Total assets673,355384,124
Current liabilities:  
Accounts payable4657,077
Accrued expenses19,64912,992
Lease liability, current portion8,9041,955
Total current liabilities29,01822,024
Long-term lease liability71,0110
Success Payment Liability5,0624,371
Deferred revenue non-current20,0140
Other long term liabilities307377
Total liabilities125,41226,772
Commitments and contingencies (See Note 7 and Note 8)
Stockholders' equity (deficit):  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, $0.001 par value; 200,000,000 shares authorized, 60,443,175 and 48,511,735 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively6149
Additional paid-in capital851,954544,381
Accumulated other comprehensive loss(920)(228)
Accumulated deficit(303,152)(186,850)
Total stockholders equity547,943357,352
Total liabilities and stockholders' equity$ 673,355$ 384,124